Inovio Pharmaceuticals (INO) has emerged as the top candidate for a short squeeze, according to recent market data. As of November 9, 2026, the stock carries a squeeze score of 92.8, driven by a significant short interest of 22.2% of its float. The borrow fee for the stock is currently 22.1%, reflecting the difficulty and cost associated with maintaining short positions in this name. With a low days-to-cover ratio of 0.8, any sudden influx of buying volume could force a rapid covering cycle. Investors should note that while high short interest is a key ingredient for a squeeze, it is a structural condition rather than a direct directional signal.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.